The U.S. Consumer Product Safety Commission is considering civil penalties against Dr. Reddy's Laboratories for allegedly disobeying rules designed to stop children from ingesting dangerous substances, the Indian drugmaker said this week in a U.S. stock exchange filing. Dr. Reddy's has been in talks with the regulator over claims that between 2008 and 2012 it violated packaging regulations for certain prescription treatments.

Full Story:

Related Summaries